Stocktoria
enGene Therapeutics Inc. ENGN
enGene Therapeutics Inc. statistics & valuation
Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($12.89); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
enGene Therapeutics Inc. trades at about 0.9× earnings — below its 10-year norm (10-year range 0.1×–5.9×, median 3.5×).
Shaded band = 10-year range (0.1×–5.9×); dot = today's 0.9×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Return on assets | -53.0% | -17.7% | -114.9% | -102.3% |
| Return on equity | -69.9% | -20.2% | -137.8% | 31.9% |
| Current ratio | 6.30 | 16.87 | 16.25 | 4.42 |
Computed from company filings · US · as of 2025-10-31. Facts plus Stocktoria's own computed scores — not investment advice.